Biora Therapeutics, Inc. · OTC:BIORQ

Biora Therapeutics — Investor Presentation (November 2023)

30 slides from Biora Therapeutics's investor presentation, Nov 13, 2023

1. Slide 1: Biora Therapeutics Corporate Presentation November 2023

   i. BIORA Therapeutics CORPORATE PRESENTATION November 2023 Exhibit 99.2

2. Slide 2: '()*+, - . !!# # ##!/0 1&*$ 2#%!#!31###% 00&$! !$1!"1 !#!!4 !!#$!2!#&# #!#& !&

   '()*+, - . !!# # ##!/0 1&*$ 2#%!#!31###% 00&$! !$1!"1 !#!!4 !!#$!2!#&# #!#& !& #!!#&!! #!$$!#!" #!#! 0! $0 # $&&#!!# #"# $&#%!#! # ##% $#!" 4 !"% $!" !%!"0 #!"$#! ## #!$#% & #&&!"!! 02!5"# &#%" &!%##& #& 0 $##&* $# $#& $# $ $!"# &#%0 * $# $#& $# $&"& $ # 0 & #&&!" #$ $# $#0! 0 & #&&!"# $&#%00 6#& !0

3. Slide 3: Our mission is to reimagine therapeutic delivery

   Our mission is to reimagine therapeutic delivery ## #%! !$ # $ %! &$ %& ! %$ "!0$6 #! 0&!!#- $& !0 #!1 #0$ 6 1$&!! &$*0" $&$ 6 0$% $ $! &!%#& $ #4 #0 #%# 0 # &!!! !" # $$%!! &

4. Slide 4: >< + %&$)$ ** $0 < ? #@ < ?&$ #@ !"#$ 6! $)$

   >< + %&$)$ 6 ** $0 < ? 0 #@ < ?&$ #@ !"#$ 6! $)$ 6 ** $0 !%&!''(!)$!% <#&! $ !& A?#!#!6 )*# +), !''(!)$!% <#&! $ !& A?#&! $ !&&% " )*# +),!''(!)$!% <#&! $ !& A ?#&! $ !&&% ) #! # A ?-+*9 % #!@ % ) #! # A?&$ #@ % @ 8! 1# $ $! !" # $$%!! &

5. Slide 5: NaviCap Targeted Oral Delivery

   NAVIcap” TARGETED CEARDEEVERY

6. Slide 6: Despite therapeutics targeting different pathways, few patients achieve long-term remission

   <+ B+ =>. - Despite therapeutics targeting different pathways, few patients achieve long-term remission - -- #%#!1* #! 0&% 6 $ $! 9G*L 0#! !! # 0!6 !0 #& #1#6 • #0$ 6 1$ )< &%69" + &!!D )F# $&! #8!&!!#& $ $!D<F • < !!#0$ # CL 0#!#!! # + #&&% $% $!1#9 #! #!# )< • 9$$ # $ # + #!#&% #& # D* < 00 &1 . #

7. Slide 7: Targeted delivery could enable rapid induction and improve patient response

   < . ) <+ B+ Targeted delivery could enable rapid induction and improve patient response / -/ - %&&$ 6!&!%#& # !&% )00 $6 0 #%!00 # 9 &%$ $!! 0&!! $ $!! 0&!!"1 ! $& 1 & !9 6! 6!!!6 & &!6! 2!&!%#& $&$6& !% 0<&%! & 6#&& ! #! # #6!$& & & 6 $&#$ 6 6 # #6 ) $ ## #!1= 9 B! 2 "$! & )" # ! A"$ 0 #!! ! $!1#&

8. Slide 8: Tissue drug concentration correlates with endoscopic outcomes in UC

   >) < -)> Tissue drug concentration correlates with endoscopic outcomes in UC #! <#!1 #& ! &!! #&#1 0 ##& ! $6 # & - 7 - 7 - 4 • 0 #!! !#& 0#& # !%)#&!%1#)& #&!%1#)& 1!!! &1#& ! #6 56 129CDMKF • #! #&!D#M9KF"&# 0 #!! ,#1%$&&2# ! && #3!&2)# 4 ! !#&#&))(# $$ #1= B! 2 "$! & )" # ! A"$ 0 #!! ! $!1#& ! !!

9. Slide 9: Needle-free, oral drug delivery to the colon

   B N -))<-)+ BO+'. Needle-free, oral drug delivery to the colon # ## $ !$!5 0 0!* $$$ -- - N $ # # $ %6#$! %&&$ 6 $ #"%&$!! 00!& 0&!9 - . &&!%#& $#% 0 $ #1$:&0 $ #"#5#% !6! 2 9+ "5%-" 2"$ #$00 ! 00 & ## $)%)$ 6 6!D)) F &$ #&# $ # !!#&= #8!P $! #%!!"A#69*9"")# " 4 !" # $$%!! &

10. Slide 10: Autonomous location and delivery to the colon

    B N -))<-)+ BO+'. Autonomous location and delivery to the colon !=QQ 1! Q&!QCGG:! !" # $$%!! &

11. Slide 11: Four successful studies in humans showing the NaviCap device was well tolerated

    )B '< <) Four successful studies in humans showing the NaviCap™ device was well tolerated and performed as intended ;K ;K ;9 ; #8#2%8$!% #8#2%8$!% #8#2%8$!% #8#2%8$!% $219%/#'$+9!'2%$##)& $219% $#%$&<$+ $219%/#'$+9!'2%$##)& $219%/#'$+9!'2%$##)& : &$#1 $$# 8$#- : &$#1;#1 : &$#1 $$# • HL 0& ! $6 • 9L

12. Slide 12: Demonstrated accurate localization and delivery to colon

    )B '< <) Demonstrated accurate localization and delivery to colon - - > /- 2# &0 1 2&%! $# $& $& #0 $ $5 ##&&$ 60# #!#% &#!&# ## &$ ! #% %#%##!1 $ $! • !!0$&$ 6 $ # & • &&! # !!# $ # • $6$! 0&% • &%! ##- !##$& !" # $$%!! &

13. Slide 13: Scintigraphic imaging of NaviCap delivery in healthy subject

    )B '< <) Scintigraphic imaging of NaviCap delivery in healthy subject #&$#)('$9%$+# #%)!%,#%$,!%* &2(?#8$&@$+# 1#8#+&(##%&+!<%$! #)A!),&1#&*%#1 8)!&&)%*#!A#3#8$#1 1AA#)#%8#&%,!$'$96 !=QQ111 ! Q$#Q%&* !R! #%6 !" # $$%!! &

14. Slide 14: Reduced systemic uptake, better distribution and tissue coverage

    *C + + <)O <+ Reduced systemic uptake, better distribution and tissue coverage #*-+!&67E&6!Q;)# ## &$ &*C D 0 #9%$:&0 $ #&$ & & F ! !#&& $$D 0 #9%F - 7 - BC7= B 7// • & &&%$ $!#$ & ! !#&& $$ • !!&%$ $! %J9S %$ #%$#% 0 $ # !!#&& $$ • )!%%!& !$ 1# !#&&9% 0 #6 &# !&!!$ $!1$ & #%!6! ! Tofacitinib Oral B

15. Slide 15: Clinical Development Plan

    *CD B N ?' F Clinical Development Plan / / )#8'%8' #%('%* 7 ; - 12!Q;) ; / / '%8' / /- - #&*%D ),)9#%1!%$ • 06P $$6 E#9&#8!%1)9#%1!%$& • ,Q) C !" # $$%!! &

16. Slide 16: Evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of BT-600 in healthy volunteers

    > 9= -+ ).<+ + ) -) <) Evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of BT-600 in healthy volunteers *C 9% M $ M !$# )9 ) ) ) G% M $ & $ & $ & )E $ & K!4 ! $ M $ $ $ $ $ *CE&6!Q;) 9%E;) M $ M .) G%E;) M K!4 ! $ M !$# )9 ) ) )E $ & $ & $ & $ & $ &P!! $ $ $ $ $ $$6 $#! - $ 0KH!4

17. Slide 17: Potential for market-leading efficacy in tofacitinib creates sizeable opportunity

    <+ B+ =. + ) Potential for market-leading efficacy in tofacitinib creates sizeable opportunity - • -$ $##$!$!0 !0 D ++ F $ $! != • TE$$ ##9 T9 TH TE • U9')* &&%!0 < C / 1',2,( #1!'F2,( -&$#G%2,( %A'3,( 1',2,( !A8$%(F%,!1H #1!'F2,( %A'3,( 9 = $7-$ $) @ #* $ % &%! . !" # $$%!! &

18. Slide 18: BioJet Systemic Oral Delivery

    BlOyet” SYSTEMIC ORAL DELIVERY

19. Slide 19: Needles are associated with poor disease management

    < . ) Needles are associated with poor disease management H L 0 $1&!&! ###4 $ & #!& #4 # # #!9" 0#!0$ ##&!# K L & #4 # # #!1#!#%# #4 $-+*9% #! %&! ## #0 &!#! E9L ##%#1##4 $-+*9 % #! ! !!#% $6 9 $# "&*$! 'A"$&V#A."$$*( $& $ # 0-+*9 % #!6!!# "&# #& # #%! &$!16)!Diabetes Ther79KDKF=E*EC& =99EQ!9**9H* #

20. Slide 20: Needle-free, oral delivery to small intestine

    AN O . )<-)+ BO+'. Needle-free, oral delivery to small intestine - • # ## $ !$!5 0 $ #0 ! 0!1$$ 1#% • # %%0 !#% 0 &%&$ 6 !$$#!# • +:&4#4 # !$$#!# 5!6! 2 / • #! • +%9 • +% !" # $$%!! &

21. Slide 21: Liquid jet delivery to the small intestine

    AN O . )<-)+ BO+'. Liquid jet delivery to the small intestine !=QQ 1! Q&!Q9G !" # $$%!! &

22. Slide 22: Excellent systemic uptake for orally delivered large molecules demonstrated in animals

    + + <+ Excellent systemic uptake for orally delivered large molecules demonstrated in animals $# $!&!#!1# &$1#& ! $$6$ &#&%%&#*%#& & B&#! # 0-+*9% #!D!%$&F 7 - - - = - / • % $ $$6 0EL± 9GLD ME7B=KLF" " &6 #%#% CL9 • !&6D 9F! 1&!$!$!1 % $ $$6 0ELD MG7B=GELF9 • $$& !&#$!! 1&& $&%$ $! #&6! !*& !#%9 • !

23. Slide 23: UPDATE: Recent experiments with next-generation autonomous device confirm consistent performance

    + + <+ UPDATE: Recent experiments with next-generation autonomous device confirm consistent performance $# $!&!#!1# &$1#& ! $$6$ &#& # !$6%%& #*%#& & B&#! # 0-+*9% #!D!%$&F 7 - - - = -- / • CL 0#$!DQF! 1&!%$& # " &6 !6! $ # $# $$6$ #$ $!9 10000 IV • $ $$60 #$!10# #$& ! 1000 PSS3/4/5 %&GL± 9GLD M7B=E

24. Slide 24: Development pathway for the BioJet platform

    + + <+ Development pathway for the BioJet™ platform ;Q;K ;9 ;Q; ;Q;K #'#)9!A1',2,(; )#8'%8'#&$%*!A +), )#8'%8'!1#'&$!&&#&& ,)!#,#%$!A2$!%!,!2& #,*'2$1# <$+ #,!$#'9 !''(!)$!)&I!'#82'#& #)A!),%8#!A !"#$ #8#2%8$!%A!)!"#$ )**#)#1!"#$ <$+!"#$ • WHL # ! • % $$6# • &% % • $&$#6 &$ 6# 6 0 !1#= $$6 0W9GL1 !&

25. Slide 25: Our mission is to reimagine therapeutic delivery

    Our mission is to reimagine therapeutic delivery ## #%! !$ # $ %! &$ %& ! %$ "!0$6 • )$ #!& ') • $###% #!9$$ • &0 # %!1 A& • 0 #%#$!&!1 $$ !8 $ $! C !" # $$%!! &

26. Slide 26: Appendix

    APPENDIX

27. Slide 27: bioratherapeutics.com/publications

    -)>< <+ bioratherapeutics.com/publications 6 ##'!,#%$!A$)*#$#1$+#)#2$8%$(!1#&A!)$+#$)#$,#%$!A%A',,$!)9(!<#'1&#&#D)!!A!A8!%8#$ !!#& ))(9 6 8!,)&!%!A&9&$#,8#)&2&$)*#$#1%$K%$(!19%$)#$,#%$!A8!'$&%128#1(91!$#$)%&A#)!A L 8#''&%$! ,8#)#8#%$&!#&))(9 6 )*#$#11#'#)9!A&!'2('#$!A8$%(8$)$#$!$+#&$#!A%A',,$!%$!,)!

28. Slide 28: bioratherapeutics.com/publications

    AN O . )<-)+ BO+'. bioratherapeutics.com/publications 6 ##'!,#%$!Aex-vivo %1in-vivo ,!1#'&$!&&#&&$+##)A!),%8#!A%!)'(!$+#)#2$81#'#)9&9&$#, M N8&2'# !!#&Controlled Release Society Annual Meeting"A$69*9K"#&American College of Gastroenterology Annual Scientific Meeting" 9*C" 6 &&#&&%*$+##)A!),%8#!A%!)'(

29. Slide 29: Diverse patent portfolio with 73 distinct patent families

    ++<+O'+ Diverse patent portfolio with 73 distinct patent families $69%#&#!#&9C#&#%$ #! #4 #!#&% #! #&1 $& '$A!), !"#$ '$A!), $+#) #8#; *%!&$8 30 patent families covering: 7 patent families covering: 36 patent families covering: • ) &!%#!"$!" • ) &!%#!"$!" • #%!$& !0 - !$#% ##!"#&#0 #% ##!"#&#0 #% #&

30. Slide 30: Slide 30

Biora Therapeutics — Investor Presentation (November 2023) on 6ix